What differentiates clinical trial statistics from preclinical methods and why robust approaches matter.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 39147752.
- Also identified by DOI 10.1038/s41467-024-51486-4 and PMC identifier 11327279.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Clinical trial statistics underlie the central decision-making process for whether a therapeutic approach can enter the clinic, but the nuances of this field may not be widely understood. Furthermore, how the statistics used in clinical trials differ from preclinical approaches and why they differ is not always clear. Here, three experts discuss the intricacies of clinical trial statistical planning and analysis as well as common issues that arise and emerging trends. The experts are Dr Tao Chen (Senior lecturer in Biostatistics at the Liverpool School of Tropical medicine), Professor Li Chao (Professor in Biostatistics at Xi’an Jiaotong University) and Professor Yang Wang (Professor in Biostatistics at the Chinese Academy of Medical Sciences and Peking Union Medical College). They have a diverse range of backgrounds across biostatistics and have been involved in numerous clinical trials of varying types.
Medical subject headings
- Clinical Trials as Topic